Quarterly report · Q3
2269.TEDINET S100Q6O2
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥798.1bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥1.01T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥770.0bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥64.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥79.0bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥66.4bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥94.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥82.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥69.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥84.9bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥47.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥87.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥56.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥49.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥61.6bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥1.21T | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥1.12T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.16T | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥466.8bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥404.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥748.1bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥713.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥696.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥87.7bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥67.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥85.9bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.8bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥36.7bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥127.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥75.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥41.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥45.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥21.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥77.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.8bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥336.24 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.13 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥607.24 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥387.81 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥135.3 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 58.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥557m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥557m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.4bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥649.9bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥649.4bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥542m |
| jpcrp040300-q3r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥45.1bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥148.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥148.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥14m |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥21.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥798.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥798.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥66.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥775m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥775m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥1.1bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥626.3bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥625.8bn |
| jpcrp040300-q3r_E21902-000Foodreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥503m |
| jpcrp040300-q3r_E21902-000Foodreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥61.7bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥144.4bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥144.1bn |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥272m |
| jpcrp040300-q3r_E21902-000Pharmaceuticalreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥18.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥770.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥770.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥775m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥80.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 522
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | Prior1YTDDuration | -45379000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -41796000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 28036000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 35393000000 | JPY |
| Increase decrease in commercial papers fin cf | Prior1YTDDuration | － | JPY |
| Increase decrease in commercial papers fin cf | CurrentYTDDuration | 25000000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -11218000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -3093000000 | JPY |
| Proceeds from issuance of bonds fin cf | Prior1YTDDuration | 9952000000 | JPY |
| Proceeds from issuance of bonds fin cf | CurrentYTDDuration | － | JPY |
| Decrease increase in treasury stock fin cf | Prior1YTDDuration | -10719000000 | JPY |
| Decrease increase in treasury stock fin cf | CurrentYTDDuration | -9496000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -23827000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -24541000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | -949000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -1430000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -1085000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -532000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -9811000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 21300000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 1895000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 4837000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 21804000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 21035000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 39011000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 64872000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YTDDuration | 16000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | － | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 60832000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 85908000000 | JPY |
| Trade notes receivable transferred by endorsement | Prior1YearInstant | 37000000 | JPY |
| Trade notes receivable transferred by endorsement | CurrentQuarterInstant | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 625827000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 144131000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 769959000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 769959000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 503000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 272000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 775000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -775000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 626330000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 144404000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 770735000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -775000000 | JPY |
| Net sales | Prior1YTDDuration | 769959000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E21902-000FoodReportableSegmentsMember | 61713000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E21902-000PharmaceuticalReportableSegmentsMember | 18388000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 80102000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |